U
WINT

UBS’s Windtree Therapeutics Inc WINT Stock Holding History

UBS’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$44K Sell
1,693
-193
-10% -$4.66K ﹤0.01% 7006
2014
Q2 		$47K Buy
1,886
+1,343
+247% +$34.3K ﹤0.01% 6965
2014
Q1 		$16K Sell
543
-778
-59% -$26.2K ﹤0.01% 8415
2013
Q4 		$42K Sell
1,321
-1,300
-50% -$40.7K ﹤0.01% 7202
2013
Q3 		$72K Buy
2,621
+1,428
+120% +$34.6K ﹤0.01% 6403
2013
Q2 		$25K Buy
+1,193
New +$29.4K ﹤0.01% 7630

Other funds holding WINT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TI
Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
TCM
Tamarack Capital Management Carlsbad, California $840M AUM 19.47% 1-Year Est. Return

UBS's WINT Position: Q3 2014 in Review

UBS increased its Windtree Therapeutics Inc (WINT) stake by 100% in Q3 2014, buying an estimated $14.1K and bringing the position to 1,167 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #7490.

UBS first reported a position in WINT in Q2 2013 and has held it in 6 quarters since. The position peaked at $471K in Q1 2014. 62 funds tracked by Wall St. Rank hold WINT as of Q3 2014.

  • UBS held 1,167 shares of Windtree Therapeutics Inc worth $30K as of Q3 2014.
  • UBS bought 583 Windtree Therapeutics Inc shares in Q3 2014, an estimated $14.1K.
  • Windtree Therapeutics Inc made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7490 holding.
  • UBS first reported a position in Windtree Therapeutics Inc in Q2 2013 and has held it in 6 quarters since.
  • UBS's Windtree Therapeutics Inc position peaked at $471K in Q1 2014.
  • 62 funds tracked by Wall St. Rank held Windtree Therapeutics Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.